Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
Identifieur interne : 003177 ( PubMed/Curation ); précédent : 003176; suivant : 003178Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
Auteurs : Antonella Sistigu [Italie] ; Takahiro Yamazaki [France] ; Erika Vacchelli [France] ; Kariman Chaba [France] ; David P. Enot [France] ; Julien Adam [France] ; Ilio Vitale [Italie] ; Aicha Goubar [France] ; Elisa E. Baracco [France] ; Catarina Remédios [France] ; Laetitia Fend [France] ; Dalil Hannani [France] ; Laetitia Aymeric [France] ; Yuting Ma [France] ; Mireia Niso-Santano [France] ; Oliver Kepp [France] ; Joachim L. Schultze [Allemagne] ; Thomas Tüting [Allemagne] ; Filippo Belardelli [Italie] ; Laura Bracci [Italie] ; Valentina La Sorsa [Italie] ; Giovanna Ziccheddu [Italie] ; Paola Sestili [Italie] ; Francesca Urbani [Italie] ; Mauro Delorenzi [Suisse] ; Magali Lacroix-Triki [France] ; Virginie Quidville [France] ; Rosa Conforti [France] ; Jean-Philippe Spano [France] ; Lajos Pusztai [États-Unis] ; Vichnou Poirier-Colame [France] ; Suzette Delaloge [France] ; Frederique Penault-Llorca [France] ; Sylvain Ladoire [France] ; Laurent Arnould [France] ; Joanna Cyrta [France] ; Marie-Charlotte Dessoliers [France] ; Alexander Eggermont [France] ; Marco E. Bianchi [Italie] ; Mikael Pittet [États-Unis] ; Camilla Engblom [États-Unis] ; Christina Pfirschke [États-Unis] ; Xavier Préville [France] ; Gilles Uzè [France] ; Robert D. Schreiber [États-Unis] ; Melvyn T. Chow [Australie] ; Mark J. Smyth [Australie] ; Enrico Proietti [Italie] ; Fabrice André [France] ; Guido Kroemer [France] ; Laurence Zitvogel [France]Source :
- Nature medicine [ 1546-170X ] ; 2014.
Descripteurs français
- KwdFr :
- ARN (métabolisme), ARN messager (génétique), ARN messager (métabolisme), Animaux, Anthracyclines (pharmacologie), Anthracyclines (usage thérapeutique), Chimiokine CXCL10 (métabolisme), Doxorubicine (pharmacologie), Doxorubicine (usage thérapeutique), Femelle, Humains, Immunocompétence (), Interféron de type I (biosynthèse), Interféron de type I (métabolisme), Métastase tumorale, Protéines adaptatrices du transport vésiculaire (métabolisme), Protéines de résistance aux myxovirus (métabolisme), Récepteur de type Toll-3 (métabolisme), Récepteur à l'interféron alpha-bêta (métabolisme), Récepteurs de reconnaissance de motifs moléculaires (métabolisme), Régulation de l'expression des gènes tumoraux (), Résultat thérapeutique, Souris de lignée C57BL, Traitement néoadjuvant, Transduction du signal (), Tumeurs du sein (anatomopathologie), Tumeurs du sein (génétique), Tumeurs du sein (immunologie), Tumeurs du sein (traitement médicamenteux).
- MESH :
- anatomopathologie : Tumeurs du sein.
- biosynthèse : Interféron de type I.
- génétique : ARN messager, Tumeurs du sein.
- immunologie : Tumeurs du sein.
- métabolisme : ARN, ARN messager, Chimiokine CXCL10, Interféron de type I, Protéines adaptatrices du transport vésiculaire, Protéines de résistance aux myxovirus, Récepteur de type Toll-3, Récepteur à l'interféron alpha-bêta, Récepteurs de reconnaissance de motifs moléculaires.
- pharmacologie : Anthracyclines, Doxorubicine.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Anthracyclines, Doxorubicine.
- Animaux, Femelle, Humains, Immunocompétence, Métastase tumorale, Régulation de l'expression des gènes tumoraux, Résultat thérapeutique, Souris de lignée C57BL, Traitement néoadjuvant, Transduction du signal.
English descriptors
- KwdEn :
- Adaptor Proteins, Vesicular Transport (metabolism), Animals, Anthracyclines (pharmacology), Anthracyclines (therapeutic use), Breast Neoplasms (drug therapy), Breast Neoplasms (genetics), Breast Neoplasms (immunology), Breast Neoplasms (pathology), Chemokine CXCL10 (metabolism), Doxorubicin (pharmacology), Doxorubicin (therapeutic use), Female, Gene Expression Regulation, Neoplastic (drug effects), Humans, Immunocompetence (drug effects), Interferon Type I (biosynthesis), Interferon Type I (metabolism), Mice, Inbred C57BL, Myxovirus Resistance Proteins (metabolism), Neoadjuvant Therapy, Neoplasm Metastasis, RNA (metabolism), RNA, Messenger (genetics), RNA, Messenger (metabolism), Receptor, Interferon alpha-beta (metabolism), Receptors, Pattern Recognition (metabolism), Signal Transduction (drug effects), Toll-Like Receptor 3 (metabolism), Treatment Outcome.
- MESH :
- chemical , biosynthesis : Interferon Type I.
- chemical , genetics : RNA, Messenger.
- chemical , metabolism : Adaptor Proteins, Vesicular Transport, Chemokine CXCL10, Interferon Type I, Myxovirus Resistance Proteins, RNA, RNA, Messenger, Receptor, Interferon alpha-beta, Receptors, Pattern Recognition, Toll-Like Receptor 3.
- chemical , pharmacology : Anthracyclines, Doxorubicin.
- chemical , therapeutic use : Anthracyclines, Doxorubicin.
- drug effects : Gene Expression Regulation, Neoplastic, Immunocompetence, Signal Transduction.
- drug therapy : Breast Neoplasms.
- genetics : Breast Neoplasms.
- immunology : Breast Neoplasms.
- pathology : Breast Neoplasms.
- Animals, Female, Humans, Mice, Inbred C57BL, Neoadjuvant Therapy, Neoplasm Metastasis, Treatment Outcome.
Abstract
Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of innate and T cell-mediated anticancer immune responses. Here we demonstrate that anthracyclines stimulate the rapid production of type I interferons (IFNs) by malignant cells after activation of the endosomal pattern recognition receptor Toll-like receptor 3 (TLR3). By binding to IFN-α and IFN-β receptors (IFNARs) on neoplastic cells, type I IFNs trigger autocrine and paracrine circuitries that result in the release of chemokine (C-X-C motif) ligand 10 (CXCL10). Tumors lacking Tlr3 or Ifnar failed to respond to chemotherapy unless type I IFN or Cxcl10, respectively, was artificially supplied. Moreover, a type I IFN-related signature predicted clinical responses to anthracycline-based chemotherapy in several independent cohorts of patients with breast carcinoma characterized by poor prognosis. Our data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens. We surmise that such 'viral mimicry' constitutes a hallmark of successful chemotherapy.
DOI: 10.1038/nm.3708
PubMed: 25344738
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003287
Links to Exploration step
pubmed:25344738Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.</title><author><name sortKey="Sistigu, Antonella" sort="Sistigu, Antonella" uniqKey="Sistigu A" first="Antonella" last="Sistigu">Antonella Sistigu</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [4] Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [4] Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Yamazaki, Takahiro" sort="Yamazaki, Takahiro" uniqKey="Yamazaki T" first="Takahiro" last="Yamazaki">Takahiro Yamazaki</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Vacchelli, Erika" sort="Vacchelli, Erika" uniqKey="Vacchelli E" first="Erika" last="Vacchelli">Erika Vacchelli</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Chaba, Kariman" sort="Chaba, Kariman" uniqKey="Chaba K" first="Kariman" last="Chaba">Kariman Chaba</name><affiliation wicri:level="1"><nlm:affiliation>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Enot, David P" sort="Enot, David P" uniqKey="Enot D" first="David P" last="Enot">David P. Enot</name><affiliation wicri:level="1"><nlm:affiliation>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Adam, Julien" sort="Adam, Julien" uniqKey="Adam J" first="Julien" last="Adam">Julien Adam</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [3] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [3] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Vitale, Ilio" sort="Vitale, Ilio" uniqKey="Vitale I" first="Ilio" last="Vitale">Ilio Vitale</name><affiliation wicri:level="1"><nlm:affiliation>Regina Elena National Cancer Institute, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Regina Elena National Cancer Institute, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Goubar, Aicha" sort="Goubar, Aicha" uniqKey="Goubar A" first="Aicha" last="Goubar">Aicha Goubar</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Baracco, Elisa E" sort="Baracco, Elisa E" uniqKey="Baracco E" first="Elisa E" last="Baracco">Elisa E. Baracco</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Remedios, Catarina" sort="Remedios, Catarina" uniqKey="Remedios C" first="Catarina" last="Remédios">Catarina Remédios</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Fend, Laetitia" sort="Fend, Laetitia" uniqKey="Fend L" first="Laetitia" last="Fend">Laetitia Fend</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Transgene S.A., Illkirch-Graffenstaden, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Transgene S.A., Illkirch-Graffenstaden</wicri:regionArea></affiliation></author><author><name sortKey="Hannani, Dalil" sort="Hannani, Dalil" uniqKey="Hannani D" first="Dalil" last="Hannani">Dalil Hannani</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Aymeric, Laetitia" sort="Aymeric, Laetitia" uniqKey="Aymeric L" first="Laetitia" last="Aymeric">Laetitia Aymeric</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Ma, Yuting" sort="Ma, Yuting" uniqKey="Ma Y" first="Yuting" last="Ma">Yuting Ma</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Niso Santano, Mireia" sort="Niso Santano, Mireia" uniqKey="Niso Santano M" first="Mireia" last="Niso-Santano">Mireia Niso-Santano</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Kepp, Oliver" sort="Kepp, Oliver" uniqKey="Kepp O" first="Oliver" last="Kepp">Oliver Kepp</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Schultze, Joachim L" sort="Schultze, Joachim L" uniqKey="Schultze J" first="Joachim L" last="Schultze">Joachim L. Schultze</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory for Genomics and Immunoregulation, Life and Medical Sciences (LIMES), University of Bonn, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Laboratory for Genomics and Immunoregulation, Life and Medical Sciences (LIMES), University of Bonn, Bonn</wicri:regionArea></affiliation></author><author><name sortKey="Tuting, Thomas" sort="Tuting, Thomas" uniqKey="Tuting T" first="Thomas" last="Tüting">Thomas Tüting</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital Bonn, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital Bonn, Bonn</wicri:regionArea></affiliation></author><author><name sortKey="Belardelli, Filippo" sort="Belardelli, Filippo" uniqKey="Belardelli F" first="Filippo" last="Belardelli">Filippo Belardelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Bracci, Laura" sort="Bracci, Laura" uniqKey="Bracci L" first="Laura" last="Bracci">Laura Bracci</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="La Sorsa, Valentina" sort="La Sorsa, Valentina" uniqKey="La Sorsa V" first="Valentina" last="La Sorsa">Valentina La Sorsa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Ziccheddu, Giovanna" sort="Ziccheddu, Giovanna" uniqKey="Ziccheddu G" first="Giovanna" last="Ziccheddu">Giovanna Ziccheddu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Sestili, Paola" sort="Sestili, Paola" uniqKey="Sestili P" first="Paola" last="Sestili">Paola Sestili</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Urbani, Francesca" sort="Urbani, Francesca" uniqKey="Urbani F" first="Francesca" last="Urbani">Francesca Urbani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Delorenzi, Mauro" sort="Delorenzi, Mauro" uniqKey="Delorenzi M" first="Mauro" last="Delorenzi">Mauro Delorenzi</name><affiliation wicri:level="1"><nlm:affiliation>1] SIB-Swiss Institute of Bioinformatics, Lausanne, Switzerland. [2] National Center of Competence in Research (NCCR) Molecular Oncology, Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. [3] Departement de Formation et Recherche, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>1] SIB-Swiss Institute of Bioinformatics, Lausanne, Switzerland. [2] National Center of Competence in Research (NCCR) Molecular Oncology, Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. [3] Departement de Formation et Recherche, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne</wicri:regionArea></affiliation></author><author><name sortKey="Lacroix Triki, Magali" sort="Lacroix Triki, Magali" uniqKey="Lacroix Triki M" first="Magali" last="Lacroix-Triki">Magali Lacroix-Triki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Centre Claudius Regaud, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Centre Claudius Regaud, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Quidville, Virginie" sort="Quidville, Virginie" uniqKey="Quidville V" first="Virginie" last="Quidville">Virginie Quidville</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Conforti, Rosa" sort="Conforti, Rosa" uniqKey="Conforti R" first="Rosa" last="Conforti">Rosa Conforti</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. [4] Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. [4] Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Spano, Jean Philippe" sort="Spano, Jean Philippe" uniqKey="Spano J" first="Jean-Philippe" last="Spano">Jean-Philippe Spano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Pusztai, Lajos" sort="Pusztai, Lajos" uniqKey="Pusztai L" first="Lajos" last="Pusztai">Lajos Pusztai</name><affiliation wicri:level="1"><nlm:affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Yale School of Medicine, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Poirier Colame, Vichnou" sort="Poirier Colame, Vichnou" uniqKey="Poirier Colame V" first="Vichnou" last="Poirier-Colame">Vichnou Poirier-Colame</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Jean Perrin Center, EA 4677 ERTICa, University of Auvergne, Clermont-Ferrand, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Jean Perrin Center, EA 4677 ERTICa, University of Auvergne, Clermont-Ferrand</wicri:regionArea></affiliation></author><author><name sortKey="Ladoire, Sylvain" sort="Ladoire, Sylvain" uniqKey="Ladoire S" first="Sylvain" last="Ladoire">Sylvain Ladoire</name><affiliation wicri:level="1"><nlm:affiliation>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon</wicri:regionArea></affiliation></author><author><name sortKey="Arnould, Laurent" sort="Arnould, Laurent" uniqKey="Arnould L" first="Laurent" last="Arnould">Laurent Arnould</name><affiliation wicri:level="1"><nlm:affiliation>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon</wicri:regionArea></affiliation></author><author><name sortKey="Cyrta, Joanna" sort="Cyrta, Joanna" uniqKey="Cyrta J" first="Joanna" last="Cyrta">Joanna Cyrta</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Dessoliers, Marie Charlotte" sort="Dessoliers, Marie Charlotte" uniqKey="Dessoliers M" first="Marie-Charlotte" last="Dessoliers">Marie-Charlotte Dessoliers</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Eggermont, Alexander" sort="Eggermont, Alexander" uniqKey="Eggermont A" first="Alexander" last="Eggermont">Alexander Eggermont</name><affiliation wicri:level="1"><nlm:affiliation>Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Bianchi, Marco E" sort="Bianchi, Marco E" uniqKey="Bianchi M" first="Marco E" last="Bianchi">Marco E. Bianchi</name><affiliation wicri:level="1"><nlm:affiliation>San Raffaele University and Scientific Institute, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>San Raffaele University and Scientific Institute, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Pittet, Mikael" sort="Pittet, Mikael" uniqKey="Pittet M" first="Mikael" last="Pittet">Mikael Pittet</name><affiliation wicri:level="1"><nlm:affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Engblom, Camilla" sort="Engblom, Camilla" uniqKey="Engblom C" first="Camilla" last="Engblom">Camilla Engblom</name><affiliation wicri:level="1"><nlm:affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Pfirschke, Christina" sort="Pfirschke, Christina" uniqKey="Pfirschke C" first="Christina" last="Pfirschke">Christina Pfirschke</name><affiliation wicri:level="1"><nlm:affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Preville, Xavier" sort="Preville, Xavier" uniqKey="Preville X" first="Xavier" last="Préville">Xavier Préville</name><affiliation wicri:level="1"><nlm:affiliation>Transgene S.A., Illkirch-Graffenstaden, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Transgene S.A., Illkirch-Graffenstaden</wicri:regionArea></affiliation></author><author><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uzè">Gilles Uzè</name><affiliation wicri:level="1"><nlm:affiliation>CNRS UMR5235, University Montpellier II, Place Eugène Bataillon, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR5235, University Montpellier II, Place Eugène Bataillon, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Schreiber, Robert D" sort="Schreiber, Robert D" uniqKey="Schreiber R" first="Robert D" last="Schreiber">Robert D. Schreiber</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri</wicri:regionArea></affiliation></author><author><name sortKey="Chow, Melvyn T" sort="Chow, Melvyn T" uniqKey="Chow M" first="Melvyn T" last="Chow">Melvyn T. Chow</name><affiliation wicri:level="1"><nlm:affiliation>Queensland Institute of Medical Research, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Queensland Institute of Medical Research, Herston, Queensland</wicri:regionArea></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>1] Queensland Institute of Medical Research, Herston, Queensland, Australia. [2] School of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>1] Queensland Institute of Medical Research, Herston, Queensland, Australia. [2] School of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea></affiliation></author><author><name sortKey="Proietti, Enrico" sort="Proietti, Enrico" uniqKey="Proietti E" first="Enrico" last="Proietti">Enrico Proietti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [4] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. [5] INSERM, U981, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [4] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. [5] INSERM, U981, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U848, Villejuif, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France. [4] Metabolomics Platform, Gustave Roussy Cancer Campus, Villejuif, France. [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U848, Villejuif, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France. [4] Metabolomics Platform, Gustave Roussy Cancer Campus, Villejuif, France. [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris</wicri:regionArea></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25344738</idno><idno type="pmid">25344738</idno><idno type="doi">10.1038/nm.3708</idno><idno type="wicri:Area/PubMed/Corpus">003287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003287</idno><idno type="wicri:Area/PubMed/Curation">003177</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003177</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.</title><author><name sortKey="Sistigu, Antonella" sort="Sistigu, Antonella" uniqKey="Sistigu A" first="Antonella" last="Sistigu">Antonella Sistigu</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [4] Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [4] Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Yamazaki, Takahiro" sort="Yamazaki, Takahiro" uniqKey="Yamazaki T" first="Takahiro" last="Yamazaki">Takahiro Yamazaki</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Vacchelli, Erika" sort="Vacchelli, Erika" uniqKey="Vacchelli E" first="Erika" last="Vacchelli">Erika Vacchelli</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Chaba, Kariman" sort="Chaba, Kariman" uniqKey="Chaba K" first="Kariman" last="Chaba">Kariman Chaba</name><affiliation wicri:level="1"><nlm:affiliation>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Enot, David P" sort="Enot, David P" uniqKey="Enot D" first="David P" last="Enot">David P. Enot</name><affiliation wicri:level="1"><nlm:affiliation>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Adam, Julien" sort="Adam, Julien" uniqKey="Adam J" first="Julien" last="Adam">Julien Adam</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [3] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [3] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Vitale, Ilio" sort="Vitale, Ilio" uniqKey="Vitale I" first="Ilio" last="Vitale">Ilio Vitale</name><affiliation wicri:level="1"><nlm:affiliation>Regina Elena National Cancer Institute, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Regina Elena National Cancer Institute, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Goubar, Aicha" sort="Goubar, Aicha" uniqKey="Goubar A" first="Aicha" last="Goubar">Aicha Goubar</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Baracco, Elisa E" sort="Baracco, Elisa E" uniqKey="Baracco E" first="Elisa E" last="Baracco">Elisa E. Baracco</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Remedios, Catarina" sort="Remedios, Catarina" uniqKey="Remedios C" first="Catarina" last="Remédios">Catarina Remédios</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Fend, Laetitia" sort="Fend, Laetitia" uniqKey="Fend L" first="Laetitia" last="Fend">Laetitia Fend</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Transgene S.A., Illkirch-Graffenstaden, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Transgene S.A., Illkirch-Graffenstaden</wicri:regionArea></affiliation></author><author><name sortKey="Hannani, Dalil" sort="Hannani, Dalil" uniqKey="Hannani D" first="Dalil" last="Hannani">Dalil Hannani</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Aymeric, Laetitia" sort="Aymeric, Laetitia" uniqKey="Aymeric L" first="Laetitia" last="Aymeric">Laetitia Aymeric</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Ma, Yuting" sort="Ma, Yuting" uniqKey="Ma Y" first="Yuting" last="Ma">Yuting Ma</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Niso Santano, Mireia" sort="Niso Santano, Mireia" uniqKey="Niso Santano M" first="Mireia" last="Niso-Santano">Mireia Niso-Santano</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Kepp, Oliver" sort="Kepp, Oliver" uniqKey="Kepp O" first="Oliver" last="Kepp">Oliver Kepp</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Schultze, Joachim L" sort="Schultze, Joachim L" uniqKey="Schultze J" first="Joachim L" last="Schultze">Joachim L. Schultze</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory for Genomics and Immunoregulation, Life and Medical Sciences (LIMES), University of Bonn, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Laboratory for Genomics and Immunoregulation, Life and Medical Sciences (LIMES), University of Bonn, Bonn</wicri:regionArea></affiliation></author><author><name sortKey="Tuting, Thomas" sort="Tuting, Thomas" uniqKey="Tuting T" first="Thomas" last="Tüting">Thomas Tüting</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital Bonn, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital Bonn, Bonn</wicri:regionArea></affiliation></author><author><name sortKey="Belardelli, Filippo" sort="Belardelli, Filippo" uniqKey="Belardelli F" first="Filippo" last="Belardelli">Filippo Belardelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Bracci, Laura" sort="Bracci, Laura" uniqKey="Bracci L" first="Laura" last="Bracci">Laura Bracci</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="La Sorsa, Valentina" sort="La Sorsa, Valentina" uniqKey="La Sorsa V" first="Valentina" last="La Sorsa">Valentina La Sorsa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Ziccheddu, Giovanna" sort="Ziccheddu, Giovanna" uniqKey="Ziccheddu G" first="Giovanna" last="Ziccheddu">Giovanna Ziccheddu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Sestili, Paola" sort="Sestili, Paola" uniqKey="Sestili P" first="Paola" last="Sestili">Paola Sestili</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Urbani, Francesca" sort="Urbani, Francesca" uniqKey="Urbani F" first="Francesca" last="Urbani">Francesca Urbani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Delorenzi, Mauro" sort="Delorenzi, Mauro" uniqKey="Delorenzi M" first="Mauro" last="Delorenzi">Mauro Delorenzi</name><affiliation wicri:level="1"><nlm:affiliation>1] SIB-Swiss Institute of Bioinformatics, Lausanne, Switzerland. [2] National Center of Competence in Research (NCCR) Molecular Oncology, Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. [3] Departement de Formation et Recherche, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>1] SIB-Swiss Institute of Bioinformatics, Lausanne, Switzerland. [2] National Center of Competence in Research (NCCR) Molecular Oncology, Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. [3] Departement de Formation et Recherche, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne</wicri:regionArea></affiliation></author><author><name sortKey="Lacroix Triki, Magali" sort="Lacroix Triki, Magali" uniqKey="Lacroix Triki M" first="Magali" last="Lacroix-Triki">Magali Lacroix-Triki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Centre Claudius Regaud, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Centre Claudius Regaud, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Quidville, Virginie" sort="Quidville, Virginie" uniqKey="Quidville V" first="Virginie" last="Quidville">Virginie Quidville</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Conforti, Rosa" sort="Conforti, Rosa" uniqKey="Conforti R" first="Rosa" last="Conforti">Rosa Conforti</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. [4] Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. [4] Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Spano, Jean Philippe" sort="Spano, Jean Philippe" uniqKey="Spano J" first="Jean-Philippe" last="Spano">Jean-Philippe Spano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Pusztai, Lajos" sort="Pusztai, Lajos" uniqKey="Pusztai L" first="Lajos" last="Pusztai">Lajos Pusztai</name><affiliation wicri:level="1"><nlm:affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Yale School of Medicine, New Haven, Connecticut</wicri:regionArea></affiliation></author><author><name sortKey="Poirier Colame, Vichnou" sort="Poirier Colame, Vichnou" uniqKey="Poirier Colame V" first="Vichnou" last="Poirier-Colame">Vichnou Poirier-Colame</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Jean Perrin Center, EA 4677 ERTICa, University of Auvergne, Clermont-Ferrand, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Jean Perrin Center, EA 4677 ERTICa, University of Auvergne, Clermont-Ferrand</wicri:regionArea></affiliation></author><author><name sortKey="Ladoire, Sylvain" sort="Ladoire, Sylvain" uniqKey="Ladoire S" first="Sylvain" last="Ladoire">Sylvain Ladoire</name><affiliation wicri:level="1"><nlm:affiliation>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon</wicri:regionArea></affiliation></author><author><name sortKey="Arnould, Laurent" sort="Arnould, Laurent" uniqKey="Arnould L" first="Laurent" last="Arnould">Laurent Arnould</name><affiliation wicri:level="1"><nlm:affiliation>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon</wicri:regionArea></affiliation></author><author><name sortKey="Cyrta, Joanna" sort="Cyrta, Joanna" uniqKey="Cyrta J" first="Joanna" last="Cyrta">Joanna Cyrta</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Dessoliers, Marie Charlotte" sort="Dessoliers, Marie Charlotte" uniqKey="Dessoliers M" first="Marie-Charlotte" last="Dessoliers">Marie-Charlotte Dessoliers</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Eggermont, Alexander" sort="Eggermont, Alexander" uniqKey="Eggermont A" first="Alexander" last="Eggermont">Alexander Eggermont</name><affiliation wicri:level="1"><nlm:affiliation>Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre</wicri:regionArea></affiliation></author><author><name sortKey="Bianchi, Marco E" sort="Bianchi, Marco E" uniqKey="Bianchi M" first="Marco E" last="Bianchi">Marco E. Bianchi</name><affiliation wicri:level="1"><nlm:affiliation>San Raffaele University and Scientific Institute, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>San Raffaele University and Scientific Institute, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Pittet, Mikael" sort="Pittet, Mikael" uniqKey="Pittet M" first="Mikael" last="Pittet">Mikael Pittet</name><affiliation wicri:level="1"><nlm:affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Engblom, Camilla" sort="Engblom, Camilla" uniqKey="Engblom C" first="Camilla" last="Engblom">Camilla Engblom</name><affiliation wicri:level="1"><nlm:affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Pfirschke, Christina" sort="Pfirschke, Christina" uniqKey="Pfirschke C" first="Christina" last="Pfirschke">Christina Pfirschke</name><affiliation wicri:level="1"><nlm:affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea></affiliation></author><author><name sortKey="Preville, Xavier" sort="Preville, Xavier" uniqKey="Preville X" first="Xavier" last="Préville">Xavier Préville</name><affiliation wicri:level="1"><nlm:affiliation>Transgene S.A., Illkirch-Graffenstaden, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Transgene S.A., Illkirch-Graffenstaden</wicri:regionArea></affiliation></author><author><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uzè">Gilles Uzè</name><affiliation wicri:level="1"><nlm:affiliation>CNRS UMR5235, University Montpellier II, Place Eugène Bataillon, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR5235, University Montpellier II, Place Eugène Bataillon, Montpellier</wicri:regionArea></affiliation></author><author><name sortKey="Schreiber, Robert D" sort="Schreiber, Robert D" uniqKey="Schreiber R" first="Robert D" last="Schreiber">Robert D. Schreiber</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri</wicri:regionArea></affiliation></author><author><name sortKey="Chow, Melvyn T" sort="Chow, Melvyn T" uniqKey="Chow M" first="Melvyn T" last="Chow">Melvyn T. Chow</name><affiliation wicri:level="1"><nlm:affiliation>Queensland Institute of Medical Research, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Queensland Institute of Medical Research, Herston, Queensland</wicri:regionArea></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>1] Queensland Institute of Medical Research, Herston, Queensland, Australia. [2] School of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>1] Queensland Institute of Medical Research, Herston, Queensland, Australia. [2] School of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea></affiliation></author><author><name sortKey="Proietti, Enrico" sort="Proietti, Enrico" uniqKey="Proietti E" first="Enrico" last="Proietti">Enrico Proietti</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [4] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. [5] INSERM, U981, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [4] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. [5] INSERM, U981, Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Kroemer, Guido" sort="Kroemer, Guido" uniqKey="Kroemer G" first="Guido" last="Kroemer">Guido Kroemer</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U848, Villejuif, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France. [4] Metabolomics Platform, Gustave Roussy Cancer Campus, Villejuif, France. [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U848, Villejuif, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France. [4] Metabolomics Platform, Gustave Roussy Cancer Campus, Villejuif, France. [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris</wicri:regionArea></affiliation></author><author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name><affiliation wicri:level="1"><nlm:affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif</wicri:regionArea></affiliation></author></analytic><series><title level="j">Nature medicine</title><idno type="eISSN">1546-170X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptor Proteins, Vesicular Transport (metabolism)</term><term>Animals</term><term>Anthracyclines (pharmacology)</term><term>Anthracyclines (therapeutic use)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (genetics)</term><term>Breast Neoplasms (immunology)</term><term>Breast Neoplasms (pathology)</term><term>Chemokine CXCL10 (metabolism)</term><term>Doxorubicin (pharmacology)</term><term>Doxorubicin (therapeutic use)</term><term>Female</term><term>Gene Expression Regulation, Neoplastic (drug effects)</term><term>Humans</term><term>Immunocompetence (drug effects)</term><term>Interferon Type I (biosynthesis)</term><term>Interferon Type I (metabolism)</term><term>Mice, Inbred C57BL</term><term>Myxovirus Resistance Proteins (metabolism)</term><term>Neoadjuvant Therapy</term><term>Neoplasm Metastasis</term><term>RNA (metabolism)</term><term>RNA, Messenger (genetics)</term><term>RNA, Messenger (metabolism)</term><term>Receptor, Interferon alpha-beta (metabolism)</term><term>Receptors, Pattern Recognition (metabolism)</term><term>Signal Transduction (drug effects)</term><term>Toll-Like Receptor 3 (metabolism)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN (métabolisme)</term><term>ARN messager (génétique)</term><term>ARN messager (métabolisme)</term><term>Animaux</term><term>Anthracyclines (pharmacologie)</term><term>Anthracyclines (usage thérapeutique)</term><term>Chimiokine CXCL10 (métabolisme)</term><term>Doxorubicine (pharmacologie)</term><term>Doxorubicine (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Immunocompétence ()</term><term>Interféron de type I (biosynthèse)</term><term>Interféron de type I (métabolisme)</term><term>Métastase tumorale</term><term>Protéines adaptatrices du transport vésiculaire (métabolisme)</term><term>Protéines de résistance aux myxovirus (métabolisme)</term><term>Récepteur de type Toll-3 (métabolisme)</term><term>Récepteur à l'interféron alpha-bêta (métabolisme)</term><term>Récepteurs de reconnaissance de motifs moléculaires (métabolisme)</term><term>Régulation de l'expression des gènes tumoraux ()</term><term>Résultat thérapeutique</term><term>Souris de lignée C57BL</term><term>Traitement néoadjuvant</term><term>Transduction du signal ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (génétique)</term><term>Tumeurs du sein (immunologie)</term><term>Tumeurs du sein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Interferon Type I</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Messenger</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adaptor Proteins, Vesicular Transport</term><term>Chemokine CXCL10</term><term>Interferon Type I</term><term>Myxovirus Resistance Proteins</term><term>RNA</term><term>RNA, Messenger</term><term>Receptor, Interferon alpha-beta</term><term>Receptors, Pattern Recognition</term><term>Toll-Like Receptor 3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anthracyclines</term><term>Doxorubicin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anthracyclines</term><term>Doxorubicin</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Interféron de type I</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gene Expression Regulation, Neoplastic</term><term>Immunocompetence</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN</term><term>ARN messager</term><term>Chimiokine CXCL10</term><term>Interféron de type I</term><term>Protéines adaptatrices du transport vésiculaire</term><term>Protéines de résistance aux myxovirus</term><term>Récepteur de type Toll-3</term><term>Récepteur à l'interféron alpha-bêta</term><term>Récepteurs de reconnaissance de motifs moléculaires</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anthracyclines</term><term>Doxorubicine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anthracyclines</term><term>Doxorubicine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Humans</term><term>Mice, Inbred C57BL</term><term>Neoadjuvant Therapy</term><term>Neoplasm Metastasis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Humains</term><term>Immunocompétence</term><term>Métastase tumorale</term><term>Régulation de l'expression des gènes tumoraux</term><term>Résultat thérapeutique</term><term>Souris de lignée C57BL</term><term>Traitement néoadjuvant</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of innate and T cell-mediated anticancer immune responses. Here we demonstrate that anthracyclines stimulate the rapid production of type I interferons (IFNs) by malignant cells after activation of the endosomal pattern recognition receptor Toll-like receptor 3 (TLR3). By binding to IFN-α and IFN-β receptors (IFNARs) on neoplastic cells, type I IFNs trigger autocrine and paracrine circuitries that result in the release of chemokine (C-X-C motif) ligand 10 (CXCL10). Tumors lacking Tlr3 or Ifnar failed to respond to chemotherapy unless type I IFN or Cxcl10, respectively, was artificially supplied. Moreover, a type I IFN-related signature predicted clinical responses to anthracycline-based chemotherapy in several independent cohorts of patients with breast carcinoma characterized by poor prognosis. Our data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens. We surmise that such 'viral mimicry' constitutes a hallmark of successful chemotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25344738</PMID><DateCreated><Year>2014</Year><Month>11</Month><Day>07</Day></DateCreated><DateCompleted><Year>2015</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat. Med.</ISOAbbreviation></Journal><ArticleTitle>Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.</ArticleTitle><Pagination><MedlinePgn>1301-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3708</ELocationID><Abstract><AbstractText>Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of innate and T cell-mediated anticancer immune responses. Here we demonstrate that anthracyclines stimulate the rapid production of type I interferons (IFNs) by malignant cells after activation of the endosomal pattern recognition receptor Toll-like receptor 3 (TLR3). By binding to IFN-α and IFN-β receptors (IFNARs) on neoplastic cells, type I IFNs trigger autocrine and paracrine circuitries that result in the release of chemokine (C-X-C motif) ligand 10 (CXCL10). Tumors lacking Tlr3 or Ifnar failed to respond to chemotherapy unless type I IFN or Cxcl10, respectively, was artificially supplied. Moreover, a type I IFN-related signature predicted clinical responses to anthracycline-based chemotherapy in several independent cohorts of patients with breast carcinoma characterized by poor prognosis. Our data suggest that anthracycline-mediated immune responses mimic those induced by viral pathogens. We surmise that such 'viral mimicry' constitutes a hallmark of successful chemotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sistigu</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [4] Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vacchelli</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaba</LastName><ForeName>Kariman</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enot</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>1] INSERM, U848, Villejuif, France. [2] Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [3] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitale</LastName><ForeName>Ilio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Regina Elena National Cancer Institute, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goubar</LastName><ForeName>Aicha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baracco</LastName><ForeName>Elisa E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remédios</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fend</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Transgene S.A., Illkirch-Graffenstaden, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannani</LastName><ForeName>Dalil</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aymeric</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niso-Santano</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kepp</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] INSERM, U848, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultze</LastName><ForeName>Joachim L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Laboratory for Genomics and Immunoregulation, Life and Medical Sciences (LIMES), University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tüting</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belardelli</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracci</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Sorsa</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziccheddu</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sestili</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urbani</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delorenzi</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] SIB-Swiss Institute of Bioinformatics, Lausanne, Switzerland. [2] National Center of Competence in Research (NCCR) Molecular Oncology, Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. [3] Departement de Formation et Recherche, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacroix-Triki</LastName><ForeName>Magali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Centre Claudius Regaud, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quidville</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conforti</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France. [4] Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spano</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pusztai</LastName><ForeName>Lajos</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier-Colame</LastName><ForeName>Vichnou</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U1015, Villejuif, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delaloge</LastName><ForeName>Suzette</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penault-Llorca</LastName><ForeName>Frederique</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pathology, Jean Perrin Center, EA 4677 ERTICa, University of Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladoire</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnould</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. [2] INSERM, CRI-866 Faculty of Medicine, Dijon, France. [3] University of Burgundy, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cyrta</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dessoliers</LastName><ForeName>Marie-Charlotte</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U981, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggermont</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Marco E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>San Raffaele University and Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittet</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engblom</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfirschke</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [2] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Préville</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Transgene S.A., Illkirch-Graffenstaden, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uzè</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CNRS UMR5235, University Montpellier II, Place Eugène Bataillon, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Melvyn T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Queensland Institute of Medical Research, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smyth</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>1] Queensland Institute of Medical Research, Herston, Queensland, Australia. [2] School of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proietti</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>André</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. [4] Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. [5] INSERM, U981, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroemer</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] INSERM, U848, Villejuif, France. [3] Université Paris Descartes, Sorbonne Paris Cité, Paris, France. [4] Metabolomics Platform, Gustave Roussy Cancer Campus, Villejuif, France. [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zitvogel</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>1] Gustave Roussy Cancer Campus, Villejuif, France. [2] Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018943">Anthracyclines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508032">Ifnar1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579071">MX1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064547">Myxovirus Resistance Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051192">Receptors, Pattern Recognition</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C519703">TLR3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>156986-95-7</RegistryNumber><NameOfSubstance UI="D053633">Receptor, Interferon alpha-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Cancer. 2014 Dec;14(12):766</RefSource><PMID Version="1">25568923</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Immunol. 2014 Dec;14(12):776-7</RefSource><PMID Version="1">25394946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Retrovirology. 2012 Jun 26;9:55</RefSource><PMID Version="1">22734835</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2011 Nov 15;71(22):6997-7009</RefSource><PMID Version="1">21948969</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gene Ther. 2008 Oct;15(20):1361-71</RefSource><PMID Version="1">18480846</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunity. 2013 May 23;38(5):855-69</RefSource><PMID Version="1">23706667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1976 Nov 2;144(5):1316-23</RefSource><PMID Version="1">186555</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2011 Mar 14;208(3):491-503</RefSource><PMID Version="1">21383056</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2009 Oct;15(10 ):1170-8</RefSource><PMID Version="1">19767732</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Rev. 2007 Dec;220:47-59</RefSource><PMID Version="1">17979839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2013 Mar 15;73(6):1709-20</RefSource><PMID Version="1">23338611</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2012 Aug;18(8):1286-90</RefSource><PMID Version="1">22772463</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2012 Sep 28;337(6102):1678-84</RefSource><PMID Version="1">23019653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunity. 2013 Apr 18;38(4):729-41</RefSource><PMID Version="1">23562161</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Apr 20;29(12):1578-86</RefSource><PMID Version="1">21422418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2011 Mar;8(3):151-60</RefSource><PMID Version="1">21364688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1987 May;6(5):1273-80</RefSource><PMID Version="1">2440675</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Apoptosis. 2007 Jan;12(1):3-18</RefSource><PMID Version="1">17080328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2010 Nov 18;6(11):e1001199</RefSource><PMID Version="1">21124994</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2011;29:235-71</RefSource><PMID Version="1">21219185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 2):S67-71</RefSource><PMID Version="1">7551417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2011 Sep 26;208(10):1989-2003</RefSource><PMID Version="1">21930769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2002 Apr 12;296(5566):301-5</RefSource><PMID Version="1">11951032</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2011 Mar 25;331(6024):1565-70</RefSource><PMID Version="1">21436444</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2011;29:185-214</RefSource><PMID Version="1">21219183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Res. 2012 Oct;22(10):1407-9</RefSource><PMID Version="1">22964712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Mar 15;19(6):1587-95</RefSource><PMID Version="1">23340299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(11):e50692</RefSource><PMID Version="1">23209811</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2007 Jun 1;23(11):1431-3</RefSource><PMID Version="1">17384020</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2004 Jul;5(7):730-7</RefSource><PMID Version="1">15208624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2010 Nov 1;16(21):5351-61</RefSource><PMID Version="1">20829329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Methods. 2012 Jul 01;9(8):805-7</RefSource><PMID Version="1">22751204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2010 Jan 15;70(2):490-500</RefSource><PMID Version="1">20068181</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2011 May 11;305(18):1873-81</RefSource><PMID Version="1">21558518</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2011 Feb 2;103(3):264-72</RefSource><PMID Version="1">21191116</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Soc Exp Biol Med. 1974 Jul;146(3):809-15</RefSource><PMID Version="1">4858239</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>EMBO J. 2009 Mar 4;28(5):578-90</RefSource><PMID Version="1">19165151</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Interferon Cytokine Res. 2006 Nov;26(11):804-19</RefSource><PMID Version="1">17115899</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2001 Oct 18;413(6857):732-8</RefSource><PMID Version="1">11607032</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Death Differ. 2009 Aug;16(8):1093-107</RefSource><PMID Version="1">19373242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2014 Jan 13;25(1):37-48</RefSource><PMID Version="1">24434209</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Physiol Rev. 2011 Oct;91(4):1219-43</RefSource><PMID Version="1">22013210</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2012 Apr 25;12(5):367-82</RefSource><PMID Version="1">22531325</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 1998 Feb;11(2):155-68</RefSource><PMID Version="1">9504686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Immunol. 2013;31:51-72</RefSource><PMID Version="1">23157435</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2012 Aug 15;72(16):3948-57</RefSource><PMID Version="1">22673234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virology. 2011 Jan 5;409(1):113-20</RefSource><PMID Version="1">21035162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2005;44(5):458-66</RefSource><PMID Version="1">16118079</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2007 Mar;8(3):203-11</RefSource><PMID Version="1">17329190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2009 Apr 1;69(7):3077-85</RefSource><PMID Version="1">19293190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2012 Jan;48(2):218-25</RefSource><PMID Version="1">22056637</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Commun. 2013;4:1833</RefSource><PMID Version="1">23673618</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2011 Mar;10(3):221-37</RefSource><PMID Version="1">21358741</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Dec 20;27(36):6129-34</RefSource><PMID Version="1">19917839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801</RefSource><PMID Version="1">21825174</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2011 Dec 16;334(6062):1573-7</RefSource><PMID Version="1">22174255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jan 1;28(1):105-13</RefSource><PMID Version="1">19917869</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Rep. 2012 Aug 30;2(2):257-69</RefSource><PMID Version="1">22854025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2012 Aug;26(8):3188-98</RefSource><PMID Version="1">22532440</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2010 Mar 19;140(6):798-804</RefSource><PMID Version="1">20303871</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Transplantation. 2008 Jul 15;86(1):137-47</RefSource><PMID Version="1">18622291</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2013 Jul;123(7):2873-92</RefSource><PMID Version="1">23778140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18490-5</RefSource><PMID Version="1">19001271</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Apr 7;434(7034):772-7</RefSource><PMID Version="1">15800576</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2010 Feb 09;10:37</RefSource><PMID Version="1">20144231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2011 Mar 1;71(5):1607-14</RefSource><PMID Version="1">21343393</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2012 Jan 06;12(2):125-35</RefSource><PMID Version="1">22222875</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2011 Sep 26;208(10):2005-16</RefSource><PMID Version="1">21930765</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2012 Jan 20;14(1):R16</RefSource><PMID Version="1">22264274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2011 Jan 20;469(7330):323-35</RefSource><PMID Version="1">21248839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2010;12(1):R5</RefSource><PMID Version="1">20064235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jun 28;366(26):2455-65</RefSource><PMID Version="1">22658128</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2014 Jan 15;74(2):436-45</RefSource><PMID Version="1">24302580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Rev. 2012 Sep;249(1):158-75</RefSource><PMID Version="1">22889221</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018943" MajorTopicYN="N">Anthracyclines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007121" MajorTopicYN="N">Immunocompetence</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064547" MajorTopicYN="N">Myxovirus Resistance Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053633" MajorTopicYN="N">Receptor, Interferon alpha-beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051192" MajorTopicYN="N">Receptors, Pattern Recognition</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051196" MajorTopicYN="N">Toll-Like Receptor 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25344738</ArticleId><ArticleId IdType="pii">nm.3708</ArticleId><ArticleId IdType="doi">10.1038/nm.3708</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003177 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003177 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25344738
|texte= Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25344738" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |